Sep 22, 2016 20:14 pm UTC| Business
TAMPA, Fla., Sept. 22, 2016 -- With 12 named storms since the Atlantic hurricane season started June 1, property management experts at The Krauss Organization are urging owners to take steps to minimize potential...
Intellipharmaceutics Responds to Recent Trading Activity
Sep 22, 2016 20:06 pm UTC| Business
TORONTO, Sept. 22, 2016 -- Intellipharmaceutics International Inc.(Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of...
Adamas Appoints Michael F. Bigham to Board of Directors
Sep 22, 2016 20:05 pm UTC| Business
EMERYVILLE, Calif., Sept. 22, 2016 -- Adamas Pharmaceuticals,Inc. (Nasdaq:ADMS) today announced the appointment of Michael F. Bigham, Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc., to its Board...
Preferred Bank Announces Quarterly Cash Dividend
Sep 22, 2016 20:05 pm UTC| Business
LOS ANGELES, Sept. 22, 2016 -- Preferred Bank (NASDAQ:PFBC), an independent commercial bank focusing on the diversified California market, today reported that the Board of Directors has declared a quarterly cash...
Sep 22, 2016 20:05 pm UTC| Business
WASHINGTON, Sept. 22, 2016 -- DuPont Fabros Technology, Inc. (NYSE:DFT), a leading owner, developer, operator and manager of enterprise-class, carrier-neutral, large multi-tenant wholesale data centers announced today...
Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
Sep 22, 2016 20:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics,...
Prothena to Host Update on PRX003 Phase 2 Development Strategy
Sep 22, 2016 20:05 pm UTC| Business
DUBLIN, Ireland, Sept. 22, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today...